The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs.

Previous
Previous

BBM Workgroup Presentation at Alzheimer’s Association International Conference 2023

Next
Next

Comorbidities can increase plasma biomarker levels associated with Alzheimer’s disease